Answers are grounded in this paper and cite their sources.
Etanercept is a tumor necrosis factor (TNF) blocking agent that has been shown to suppress ongoing experimental autoimmune myasthenia gravis (EAMG). This subcutaneously administered TNF blocking agent has also been shown to be safe and effective in several rheumatological diseases including rheumatoid arthritis, psoriasis, and ankylosing spondylitis. A prospective clinical pilot trial of etanercept in corticosteroid-dependent autoimmune myasthenia gravis (MG) patients supports further study into etanercept as a treatment for MG.
No takes yet. Share an insight, caveat, or question.
Julie Rowin (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: